Latest by Myles Helfand

This Week in HIV Research: Treatment Does a Body Good

Early treatment reduces health risks; on-demand PrEP more popular than daily pill among French MSM; long-acting injectable PrEP preferred over daily pill in Swaziland; HIV-positive MSM aren’t testing for syphilis enough.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Another Notch in the 'Treatment as Prevention' Belt

“Opposites Attract” study piles on more data backing U=U; mixed results on enhanced HIV interventions among African sex workers; the tipping point for re-engagement in HIV care; thyroid function in the modern treatment era.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Mitigating an ICE-y Reception

HIV ramifications of the Trump administration’s anti-immigration efforts; HIV in plasma vs. rectal tissue; how HCV treatment affects HIV/HCV coinfection; HPV vaccination efficacy among women with HIV.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: A Yawning Racial Gap in U.S. Testing

HIV testing disparities among black MSM in the Southern U.S.; reasons for non-adherence in a vaginal HIV prevention ring trial; the importance of PrEP despite successful HIV treatment; inaccurate antiretroviral usage rates in Africa.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: At-Home PrEP Care Advances

Fewer health care visits for PrEP recipients; sexual behavior in the U=U era; HIV and bone issues in women; how Medicaid enrollment gaps affect HIV treatment success.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Key Measures of Success Lag in the U.S. South

Lower CD4, higher viral load in the U.S. South; HIV testing among U.S. heterosexuals; heightened seroconversion risk around childbirth; predicting success for long-acting, injectable PrEP.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Not-So-Routine Testing

Missed chances for HIV testing; depressive symptoms associated with detectable HIV viral load; perceived HIV discrimination declines overall; zoledronic acid beats TDF switching for bone mass improvement.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Missed Opportunities to Close the Gap

Missed opportunities to prescribe PrEP to at-risk people; long-term viral suppression reduces cancer risk; sexual health clinics and linkage to care; neurocognitive benefits of low-dose hydrocortisone therapy for women.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Self-Testing Passes a Big Test

HIV self-testing vs. professional HIV testing; the most effective influenza vaccine strategies for people with HIV; how age can affect flu vaccine efficacy; early HIV treatment and CD4:CD8 ratio normalization.

By Barbara Jungwirth and Myles Helfand

Is the World Ready for Long-Acting HIV Treatment?

How can science improve on its own miracle? This is the conundrum at the heart of an ongoing conversation in HIV medicine over the future of long-acting antiretroviral therapy, or LA-ART. The promise of LA-ART lies in the freedom it can potentially offe...

By Myles Helfand